Investors in BioCryst Pharmaceuticals, Inc. (BCRX) saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BCRX options chain for the new May 17th contracts and identified one put and one call contract of particular interest.
The put contract at the $10.00 strike price has a current bid of $1.45. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $10.00, but will also collect the premium, putting the cost basis of the shares at $8.55 (before broker commissions). To an investor already interested in purchasing shares of BCRX, that could represent an attractive alternative to paying $10.20/share today.
Because the $10.00 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 61%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 14.50% return on the cash commitment, or 103.77% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for BioCryst Pharmaceuticals, Inc., and highlighting in green where the $10.00 strike is located relative to that history: